In the recent StopPRE randomized trial, participants with high-risk first trimester screening, started on aspirin prophylaxis, and subsequent low-risk sFlt1/PlGF (≤38) screening at 24–28 weeks, were randomized 1:1 to discontinuation of aspirin therapy or ongoing treatment, given a concern for aspirin-associated morbidity.78 The authors demonstrated non-inferiority to discontinuing aspirin prophylaxis for the primary outcome of preterm preeclampsia. Here, PGF is linked to preeclampsia.